Coming soon

Events

See what BetaGlue will attend
San Francisco - JP Morgan Health Conference

44th Annual J.P. Morgan

Healthcare Conference

January 12-15, 2026 | San Francisco, California

Register interest: info@betaglue.com


Alexis
Peyroles
CEO
Salvatore
Calabrese
CFO
Gianluca
De Danieli
Head of Clinical Development
Spectrum Miami

Advancements in the fight against cancer

Spectrum Conference

January 15-17, 2026 | Miami (FL), USA

Register interest: info@betaglue.com


Alexis
Peyroles
CEO
Salvatore
Calabrese
CFO
Gianluca
De Danieli
Head of Clinical Development
MioLive - Roma

World Congress of Interventional Oncology

MIOLive

January 26-27, 2026 | Rome

Register interest: info@betaglue.com


Gianluca
De Danieli
Head of Clinical Development

What we’re building

News

Discover the latest from our lab and clinic
BetaGlue® Technologies SpA Announces Rebrand & Introduces YntraDose®
Website Launch

BetaGlue® Technologies SpA Announces Rebrand & Introduces YntraDose®

Milan, April 30, 2024 – BetaGlue Technologies S.p.A. (“BetaGlue” or the “Company”) a clinical-stage company developing novel radiotherapy products for the personalised treatment of solid tumour cancers today announces the…

Read more
1200 800 Betaglue® Therapeutics
BetaGlue® Secures €10m EIC Accelerator Award
EU Logo

BetaGlue® Secures €10m EIC Accelerator Award

Milan, March 4, 2024 – BetaGlue Technologies S.p.A. (“BetaGlue” or the “Company”) a clinical stage company developing novel medical device products in the field of loco-regional radiotherapy to treat solid…

Read more
1200 800 Betaglue® Therapeutics
BetaGlue® Appoints Salvatore Calabrese as Chief Financial Officer
Salvatore Calabrese CFO, BetaGlue

BetaGlue® Appoints Salvatore Calabrese as Chief Financial Officer

Milan, January 15, 2024 – BetaGlue Technologies S.p.A. (“BetaGlue” or the “Company”) a clinical stage company developing novel medical device products with a primary focus in the field of loco-…

Read more
1200 800 Betaglue® Therapeutics